Trial · NCT03435640
Participant flow33
How many started, completed or left each group, period by period.
1 to 20 of 33
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Cohort 1 NKTR-262 (0.03 mg) + Bempegaldesleukin (Administered Staggered) | 3 | |
| Overall Study | STARTED | Cohort 2 NKTR-262 (0.06 mg) + Bempegaldesleukin (Administered Staggered) | 3 | |
| Overall Study | STARTED | Cohort 3 NKTR-262 (0.06 mg) + Bempegaldesleukin (Administered the Same Day) | 4 | |
| Overall Study | STARTED | Cohort 4 NKTR-262 (0.12 mg) + Bempegaldesleukin (Administered the Same Day) | 3 | |
| Overall Study | STARTED | Cohort 5 NKTR-262 (0.24 mg) + Bempegaldesleukin (Administered the Same Day) | 4 | |
| Overall Study | STARTED | Cohort 6 NKTR-262 (0.48 mg) + Bempegaldesleukin (Administered the Same Day) | 4 | |
| Overall Study | STARTED | Cohort 7 NKTR-262 (0.96 mg) + Bempegaldesleukin (Administered the Same Day) | 4 | |
| Overall Study | STARTED | Cohort 8 NKTR-262 (1.92 mg) + Bempegaldesleukin (Administered the Same Day) | 3 | |
| Overall Study | STARTED | Cohort 9 NKTR-262 (3.84 mg) + Bempegaldesleukin (Administered the Same Day) | 8 | |
| Overall Study | STARTED | Cohort A NKTR-262 (3.84 mg) + Bempegaldesleukin (Administered the Same Day) | 14 | |
| Overall Study | STARTED | Cohort B NKTR-262 (3.84 mg) + Bempegaldesleukin + Nivolumab | 14 | |
| Overall Study | COMPLETED | Cohort 1 NKTR-262 (0.03 mg) + Bempegaldesleukin (Administered Staggered) | 3 | |
| Overall Study | COMPLETED | Cohort 2 NKTR-262 (0.06 mg) + Bempegaldesleukin (Administered Staggered) | 2 | |
| Overall Study | COMPLETED | Cohort 3 NKTR-262 (0.06 mg) + Bempegaldesleukin (Administered the Same Day) | 3 | |
| Overall Study | COMPLETED | Cohort 4 NKTR-262 (0.12 mg) + Bempegaldesleukin (Administered the Same Day) | 1 | |
| Overall Study | COMPLETED | Cohort 5 NKTR-262 (0.24 mg) + Bempegaldesleukin (Administered the Same Day) | 4 | |
| Overall Study | COMPLETED | Cohort 6 NKTR-262 (0.48 mg) + Bempegaldesleukin (Administered the Same Day) | 4 | |
| Overall Study | COMPLETED | Cohort 7 NKTR-262 (0.96 mg) + Bempegaldesleukin (Administered the Same Day) | 1 | |
| Overall Study | COMPLETED | Cohort 8 NKTR-262 (1.92 mg) + Bempegaldesleukin (Administered the Same Day) | 3 | |
| Overall Study | COMPLETED | Cohort 9 NKTR-262 (3.84 mg) + Bempegaldesleukin (Administered the Same Day) | 8 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03435640/flow